Offering exceptional value throughout the continuum of care, Marquette 12SL analyzes simultaneously acquired 12-lead ECGs; makes precise measurementsof recorded cardiac signals; and provides an interpretation of the ECG waveforms using classic and newly developed ECG interpretation criteria for both rhythm and morphology.

This computerized analysis program operates on a variety of platforms and currently serves these areas: 

  • Pre-hospital environment 
  • Emergency department 
  • General hospital departments 
  • CCU/ICU 
  • Exercise testing labs 
  • Clinics
  • Physician offices

Clinically validated improvements
Ever-focused on improving accuracy and enhancing patient care, Marquette 12SL is continually refined through the following processes:

  • Regular clinical input: Annual input is gathered from the world’s top consulting cardiologists and physicians—focusing on research and development efforts.
  • Clinically correlated databases: GE utilizes many different databases during the development and validation process to enhance program accuracy. This helps preclude us from developing an analysis program that works well on training sets of ECGs, but cannot be applied with the same success to other populations.

Beyond databases 
Clinically correlated databases help to improve program accuracy, but they also have limitations. Analysis programs must work with a wider spectrum of ECG data. To accomplish this task, GE measures its analysis program performance on a large database of ECGs (>150,000). This process confronts the program with multiple diseases and varying degrees of abnormality. ECGs that change their analysis results due to program modification can be further investigated with expert confirmation.


The GE Marquette 12SL analysis program supports clinical decision-making accuracy and reproducibility by providing consistent analysis and comparison of ECG waveforms. Features include: 

  • ECG analysis with precise measurement1 and interpretation to support excellence in clinical care 
  • Arrhythmia and chest pain assessment capabilities, gender-specific criteria, and risk stratification tools 
  • Paediatric age-driven interpretation criteria 
  • Automated second opinion
  • Innovation in technology and applications


Marquette 12SL ECG Analysis–at a glance: 

  • Meets current standards for 15-lead acquisition and analysis for paediatric patients2 
  • Offers automated second opinion that has clinical verified accuracy
  • Offers arrhythmia analysis including those for atrial arrhythmias, pace detection, and QT measurement
  • Suggests additional findings not initially detected and encourages careful, targeted review of the ECG tracing 
  • Minimizes the time spent over-reading ECGs3 
  • Provides accurate, validated measurements of heart rate, axis, intervals, and durations
  • Offers pediatric age-driven interpretation criteria
  • Offers adult gender- and age-driven interpretation criteria for acute MI; utilized in pre-hospital defibrillators to identify clinically significant changes and expedite patient care in time-critical environments 
  • Assists with ECG interpretation training assistance 
  • Offers pioneering technology innovation and expertise; by serving patients through the entire cardiac experience, from pre-hospital through follow up


A suite of ECG analysis
With the arrhythmia and chest pain assessment capabilities, gender-specific criteria, and risk stratification tools of Marquette 12SL, a wider range of disease management needs can be addressed. This helps physicians make more efficient and informed clinical decisions. 

  • Serial ECG comparison: The Marquette 12SL ECG analysis program and the Marquette* Serial comparison program provide a consistent analysis and comparison of waveforms across each and every ECG, helping ensure reproducibility and objectivity through all phases of patient care. 
    • Provides department supervisors with a means too run efficient operations. 
    • Utilizes interpretive statements, ECG measurements and waveform comparison techniques to maximize performance and accuracy in the detection off clinically significant changes.
    • Emulates the techniques used by trained electrocardiographers when comparing serial ECGs.
  • Gender-specific criteria: Marquette 12SL with gender-specific interpretation applies new criteria for evaluating the ST segment and T-wave off the ECG waveform, improving sensitivity to acute MI’s in women and enhancing diagnostic confidence. 
    • 14% improved detection of acute anterior MI in women under 60 years of age.4 
    • 28% improved detection of acute inferior MI in women under 60 years of age without sacrificing the high specificity already maintained by the program.5
    • Assists physicians in thee detection off acute MI in women. 
  • Acute Cardiac Ischemia Time-Insensitive Predictive Instrument (ACI-TIPI): Marquette 12SL with ACI-TIPI is a mathematical algorithm that predicts the probability of cardiac ischemia. Working in conjunction with Marquette 12SL ECG Analysis Program measurements, this algorithm presents a numerical “score” that represents the probability that a particular patient has acute cardiac ischemia.



1. GE Healthcare, Marquette 12SL ECG Analysis Program Physician's Guide, 2036070-006, Statement of Validation and Accuracy.
2. Schwartz PJ, Garson A Jr, Paul T, Stramba-Badiale M, Vetter VL, Wren C. “Guidelines for the interpretation of the neonatal electrocardiogram. A task force of the European Society of Cardiology.” Eur Heart J 2002 Sep;23(17):1329-44.
3. Brailer DJ, Kroch E, Pauly MV. “The Impact of Computer-assisted Test Interpretation on Physician Decision Making: The Case of Electrocardiograms” Med Decis Making. 1997 Jan-Mar;17(1):80-6
4. Wright, R.S., et.al. “Women with Acute Anterior Myocardial Infarction Have Less Precordial ST Elevation Than Men Independent of Age of Presentation.” J Am Coll Cardiol. 37(2001): 361A.
5. Xue, J., et.al. “A New Method to Incorporate Age and Gender Into the Criteria for the Detection of Acute Inferior Myocardial Infarction.” J Electrocardiol. 34(4)(Part 2)(Oct 2001): 229-234.